Century Therapeutics, Inc. Common Stock (IPSC) Stock
Key stats
- Market cap
- $315.07M
- Price / Earnings ratio
- -2.8x
- EPS (TTM)
- -$0.93
- Volume
- Loading
- 52-week high
- $3.04
- 52-week low
- $0.44
Source: third-party data provider, as of November 13, 2026
Compare with IPSC
Recent news

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
IPSC

IHI Power Services Corp. Rebrands as Kyuden Energy Partners Following Acquisition by Japan's Kyuden Group
IHI Power Services Corp. Rebrands as Kyuden Energy Partners Following Acquisition by Japan's Kyuden Group
IPSC

Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
IPSC

Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
IPSC
Technical indicators
- RSI 14
- 56.66
- MACD 12/26/9
- 0.02
- EMA 9 of MACD
- -0.02
- MACD histogram
- 0.04
- SMA 50
- $1.66
- Price above SMA 50
- EMA 50
- $1.67
- Price above EMA 50
- SMA 200
- $2.07
- Price below SMA 200
- EMA 200
- $1.81
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
IPSC

IHI Power Services Corp. Rebrands as Kyuden Energy Partners Following Acquisition by Japan's Kyuden Group
IHI Power Services Corp. Rebrands as Kyuden Energy Partners Following Acquisition by Japan's Kyuden Group
IPSC

Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
IPSC

Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
IPSC

Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors
Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors
IPSC

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
IPSC

5 Health Care Stocks That Are Diving - And May Rally
5 Health Care Stocks That Are Diving - And May Rally
IPSC

Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies
Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies
IPSC
About Century Therapeutics, Inc. Common Stock
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Brent Pfeiffenberger M.B.A., Pharm.D. | President, CEO & Chairman | 1978 |
| Dr. Gregory Russotti Ph.D. | Chief Technology & Manufacturing Officer | 1967 |
| Dr. Chad A. Cowan Ph.D. | Chief Scientific Officer | 1972 |
| Mr. Douglas Carr CPA | Senior VP of Finance & Operations, Principal Financial Officer and Secretary | — |
| Krista Kauppinen J.D., Ph.D. | VP, General Counsel & Head of Intellectual Property | — |
| Ms. Megan Bilson | Chief People Officer | — |
| Michael Naso Ph.D. | Senior VP of Cell Engineering | — |
| Ms. Elizabeth Devlin | VP & Head of Development | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 56.66
- MACD 12/26/9
- 0.02
- EMA 9 of MACD
- -0.02
- MACD histogram
- 0.04
- SMA 50
- $1.66
- Price above SMA 50
- EMA 50
- $1.67
- Price above EMA 50
- SMA 200
- $2.07
- Price below SMA 200
- EMA 200
- $1.81
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -9.2 | -3.8 | ||||||||||
| 2022 | -18.2 | +13.9 | -10.7 | -1.9 | -29.4 | -4.5 | +20.3 | +1.2 | -6.7 | +4.6 | -2.1 | -51.4 |
| 2023 | -8.0 | -0.2 | -22.9 | -9.0 | -0.9 | -0.3 | -2.9 | -17.9 | -19.0 | -19.0 | -8.1 | +133.8 |
| 2024 | +17.6 | -13.2 | +5.6 | -28.1 | -2.3 | -14.4 | -7.5 | -15.8 | +4.3 | -30.3 | +36.5 | -39.9 |
| 2025 | -21.2 | -12.8 | -21.3 | +20.0 | -5.4 | +3.7 | +1.9 | -7.5 | +4.2 | +16.0 | -8.3 | +83.3 |
| 2026 | +91.9 | +26.1 | +0.0 | +4.6 | +6.1 | +3.8 | -15.5 | +3.5 | -15.8 | -8.7 | +17.6 |



